Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 13/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1538594 | 0.77 | DAO (0.46) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL3075340 | 0.74 | AOC3 (0.44) | DAOMETAP2METAP1KDR | |
| SCHEMBL3672721 | 0.73 | RIPK1 (0.54) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL2722440 | 0.72 | CCNB2 (0.43) | CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL22134394 | 0.71 | DAO (0.47) | DAOCDK1METAP2METAP1 | |
| SCHEMBL4314234 | 0.70 | DAO (0.47) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL575029 | 0.69 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL30678374 | 0.69 | DAO (0.62) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL2595303 | 0.69 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL1176828 | 0.69 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1034 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024001967-A1 | IMIDAZONAPHTHYRIDINE COMPOUND WITH AFFINITY WITH TAU PROTEIN, METHOD FOR PREPARING SAME, AND USE THEREOF | 北京师范大学 | 2024-01-04 | — | — | WO | claimed |
| CN-115322197-B | Imidazonaphthyridine compound with affinity with Tau protein, and preparation method and application thereof | 北京师范大学 | 2023-09-29 | — | — | CN | claimed |
| CN-111592540-B | Imidazonaphthyridine high-performance photoelectric material and application thereof | 烟台九目化学股份有限公司 | 2022-12-27 | — | — | CN | claimed |
| CN-115322197-A | Imidazonaphthyridine compound with affinity to Tau protein and preparation method and application thereof | 北京师范大学 | 2022-11-11 | — | — | CN | claimed |
| CN-111592540-A | Imidazonaphthyridine high-performance photoelectric material and application thereof | 烟台九目化学股份有限公司 | 2020-08-28 | — | — | CN | claimed |
| US-10071156-B2 | Aqueous gel formulations containing immune response modifiers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-09-11 | — | — | US | claimed |
| EP-3344262-A1 | IMMUNE CELLS HAVING INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE OF THE SAME | Innate Tumor Immunity, Inc. (US) | 2018-07-11 | — | — | EP | claimed |
| WO-2017040670-A1 | IMMUNE CELLS HAVING INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE OF THE SAME | IFM THERAPEUTICS, INC (US) | 2017-03-09 | — | — | WO | claimed |
| US-20170056448-A1 | IMMUNE CELLS HAVING INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE OF THE SAME | IFM THERAPEUTICS, INC (US) | 2017-03-02 | — | — | US | claimed |
| US-20160101173-A1 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-04-14 | — | — | US | claimed |
| EP-1140091-A2 | FORMULATIONS COMPRISING IMIQUIMOD OR OTHER IMMUNE RESPONSE MODIFIERS FOR TREATING MUCOSAL CONSITIONS | 3M Innovative Properties Company (US) | 2001-10-10 | — | — | EP | claimed |
| US-6245776-B1 | DRUG MIXTURE OF IMMUNE RESPONSE MODIFIER, FATTY ACID, PRESERVATIVE AND CARBOMER | 3M INNOVATIVE PROPERTIES COMPANY | 2001-06-12 | — | — | US | claimed |
| WO-2000040228-A2 | FORMULATIONS COMPRISING IMIQUIMOD OR OTHER IMMUNE RESPONSE MODIFIERS FOR TREATING MUCOSAL CONDITIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-07-13 | — | — | WO | claimed |
| EP-0459505-B1 | Imidazonaphthyridine derivatives | KYOWA HAKKO KOGYO KK (JP) | 1996-10-02 | — | — | EP | claimed |
| US-5536730-A | ANTIINFLAMMATORY, ANTIALLERGIC AND BRONCHODILATIVE ACTIVITY | KYOWA HAKKO KOGYO CO. LTD. (JP) | 1996-07-16 | — | — | US | claimed |
| US-5484924-A | ANTIALLERGEN, ANTIINFLAMMATORY, ANTIASTHMA | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-01-16 | — | — | US | claimed |
| US-5468756-A | Antiinflammatory, antiallergen | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-11-21 | — | — | US | claimed |
| US-5364859-A | Antiinflammatory agents, antiallergens, bronchodilators | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-11-15 | — | — | US | claimed |
| EP-0614897-A1 | IMIDAZONAPHTHYRIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-09-14 | — | — | EP | claimed |
| EP-0459505-A1 | Imidazonaphthyridine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-12-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071156-B2 | Aqueous gel formulations containing immune response modifiers | IFNG, ICOS, IL4 | DAO 1689/4885RIPK1 1412/4885CCNB2 1438/4885 |
| US-20170056448-A1 | IMMUNE CELLS HAVING INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE OF THE SAME | IL2, IFNG, IL2RA | DAO 4572/4885RIPK1 773/4885CCNB2 3104/4885 |
| US-20160101173-A1 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS | IFNG, ICOS, IL4 | DAO 1689/4885RIPK1 1412/4885CCNB2 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.